Attributable costs of patients with candidemia and potential implications of polymerase chain reaction–based pathogen detection on antifungal therapy in patients with sepsis
Autor: | Eberhard Straube, Konrad Reinhart, Svea Sachse, Ole Bayer, Andreas Kortgen, Frank Bloos |
---|---|
Rok vydání: | 2013 |
Předmět: |
medicine.medical_specialty
medicine.diagnostic_test Septic shock business.industry Case-control study Retrospective cohort study Critical Care and Intensive Care Medicine medicine.disease Intensive care unit law.invention Sepsis law Internal medicine Multiplex polymerase chain reaction medicine Blood culture Intensive care medicine business Polymerase chain reaction |
Zdroj: | Journal of Critical Care. 28:2-8 |
ISSN: | 0883-9441 |
Popis: | Purpose The purposes of this study were to calculate attributable costs of candidemia in patients with severe sepsis and to obtain preliminary data regarding the potential effects of polymerase chain reaction–based pathogen detection on antifungal therapy for these patients. Methods Patients treated between 2004 and 2010 because of severe sepsis were included into this retrospective analysis. The hospital management provided annual fixed costs per patient-day; data for variable intensive care unit costs were taken from the literature. Multiplex polymerase chain reaction (PCR) was used (VYOO®, SIRS-Lab, Jena, Germany) for pathogen detection in the blood. Results Thirty-two patients with candidemia were identified. Of 874 patients with sepsis, propensity score matching found 32 corresponding patients with sepsis but without candida infection but similar risk factors for developing candidemia. Attributable costs of candidemia were 7713.79 Euro (cost increase, 19.4%). Initiation of antifungal therapy was reduced from 67.5 (52.4, 90) hours in the group, where candida infection was determined by blood culture, to 31.0 (28.0, 37.5; P Conclusions Candidemia increases costs of care in patients with septic shock. Polymerase chain reaction–based pathogen detection significantly reduces the time to initiation of antifungal therapy. This might impact on the clinical course of the disease but need to be confirmed in further trials. |
Databáze: | OpenAIRE |
Externí odkaz: |